09/12/23 4:05 PMNasdaq : EIGR clinical trialEiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaEiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta.RHEA-AIneutral
09/05/23 4:05 PMNasdaq : EIGR conferencesEiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceEiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25 th Annual Global Investment Conference on...RHEA-AIneutral
08/14/23 4:05 PMNasdaq : EIGR earningsEiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateResources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian, MD, PhD, MBA, appointed CEO. PALO ALTO, Calif., Aug. 14, 2023/...RHEA-AIneutral
06/29/23 8:00 AMNasdaq : EIGR Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEOPrioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024 David Apelian, MD, PhD, MBA, appointed CEO Live conference call and...RHEA-AIneutral
06/28/23 4:05 PMNasdaq : EIGR conferencesEiger BioPharmaceuticals to Host Business Update Call TomorrowEiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise,...RHEA-AIneutral
05/11/23 4:00 PMNasdaq : EIGR earningsEiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateEiger BioPharmaceuticals, Inc., a...RHEA-AIneutral
05/03/23 4:05 PMNasdaq : EIGR Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and...RHEA-AIvery positive
04/13/23 8:00 AMNasdaq : EIGR Eiger BioPharmaceuticals Strengthens Management Team with New AppointmentsEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical companyRHEA-AIpositive
03/16/23 4:28 PMNasdaq : EIGR earningsEiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateEiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update. "In December, we announced that both our lonafarnib-based...RHEA-AIpositive
02/08/23 5:00 PMNasdaq : EIGR clinical trialcovid-19New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine. The...RHEA-AIneutral